Gelatin
This article was originally published in The Tan Sheet
Executive Summary
Interim results of new study on gelatin will be discussed at an FDA TSE advisory committee meeting in June, CDER Office of New Drug Chemistry Director Yuan-yuan Chiu, PhD, announces at consumer briefing on BSE and TSE held April 16. "Validation of inactivation" study, conducted by Gelatin Manufacturers of Europe, is evaluating effect of gelatin processing on a spongiform agent's ability to spread infection. Chiu also asserts there is no basis for objections to using gelatin produced from cattle residing in BSE-contaminated countries